October 26, 2022
FDA: Class I recall of Jiangsu Well Biotech COVID-19 Ag Rapid Test
Editor's Note
The Food and Drug Administration (FDA) on October 12 identified the recall of Jiangsu Well Biotech’s COVID-19 Ag Rapid Test Devices as Class I, the most serious.
The recall was initiated because the tests were distributed to US customers without authorization, clearance, or approval from the FDA.
No complaints, injuries, or deaths have been reported.
Distribution dates were July 23, 2021 to January 23, 2022.
Free Daily News
- Back to Business: Budgeting for Sustainable Staffing Models in the OR
- Healthcare job gain in August offset by losses in federal government, other industries
- AHA study: HOPD Medicare patients are poorer, sicker, more rural than those seen in physician offices
- ACS, Lifesaving Technologies launch nationwide effort to expand bleeding control readiness
- Minimally invasive ICH surgery evacuates clot fast but fails to improve 6-month outcomes
- Rural hospitals face crisis under OBBBA as experts call for cohesive reform
- AMA urges health systems to act now on AI governance
- Suicide Prevention Month: Hospitals prepare for new The Joint Commission suicide prevention goal, effective 2026
- Survey: Perioperative leaders adapt to supply strain, staffing pressure, ASC growth
- Gait retraining eases knee osteoarthritis pain as effectively as medication, can delay knee surgery
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement